Last reviewed · How we verify
EDP1815 tablet
At a glance
| Generic name | EDP1815 tablet |
|---|---|
| Also known as | Prevotella histicola |
| Sponsor | Evelo Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (PHASE2, PHASE3)
- Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms (PHASE1)
- A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EDP1815 tablet CI brief — competitive landscape report
- EDP1815 tablet updates RSS · CI watch RSS
- Evelo Biosciences, Inc. portfolio CI